Thymalin
A thymic peptide complex studied for immune system restoration, particularly in aging populations and immunocompromised states.
What is Thymalin?
Thymalin is a peptide complex originally isolated from the thymus gland by Vladimir Khavinson and Vladimir Morozov in the 1970s. It contains the dipeptides L-Glu-L-Trp (EW) and L-Lys-L-Glu (KE) among other thymic factors. It has been used in Russian clinical practice for decades to support immune function, particularly in elderly patients, those recovering from infections, and as an adjunct in oncology. A landmark 6-year clinical trial demonstrated that combined thymalin and epithalamin treatment reduced mortality by nearly 2-fold in elderly patients.
What Thymalin Is Investigated For
Thymalin is investigated primarily for immune restoration in elderly and immunocompromised populations, with additional claims around longevity, thymic function support, and infection-related immunocorrection. The strongest evidence is a landmark 6-year elderly-cohort study from the Khavinson group showing that thymalin plus epithalamin reduced mortality nearly 2-fold, supported by additional Russian clinical work in elderly post-surgical, tuberculosis, and recent COVID-19 complex-therapy contexts. Constituent dipeptides EW (Thymagen) and KE (Vilon) have been isolated and shown to regulate gene expression in immune pathways. The honest caveats are significant: virtually all evidence comes from the Khavinson research program and Russian clinical network, independent Western replication under modern trial-methodology standards is absent, and the heterogeneous nature of the calf-thymus extract means component identity and batch consistency are less rigorously characterized than a single-molecule peptide. The lifelong-repeated-course schedule used in Russian longevity protocols has not been evaluated by independent Western pharmacovigilance, and research-chemical supply outside Russian pharmaceutical channels varies substantially in component profile.
History & Discovery
Thymalin emerged from work by Vladimir Khavinson and Vladimir Morozov at what would become the St. Petersburg Institute of Bioregulation and Gerontology, beginning in the early 1970s. The original preparation was an extract of calf thymus tissue, processed to yield a complex of low-molecular-weight peptides intended to mimic endogenous thymic factors that decline with age and immune injury. By the 1980s the Khavinson group had moved from the crude extract toward identifying its active dipeptide components — most notably L-Glu-L-Trp (later marketed as Thymagen) and L-Lys-L-Glu (later marketed as Vilon). Thymalin is one of the older and arguably most clinically-studied bioregulators in the Khavinson catalog. It has decades of registered use in Russian and CIS clinical practice, primarily as an immunomodulator in elderly, post-surgical, and infection-recovery contexts, and it features prominently in the multi-year elderly-cohort study that is the program's flagship longevity claim. The lineage is distinct from the Western thymic peptide tradition — Thymosin Alpha-1 was identified independently by Allan Goldstein at Albert Einstein College of Medicine in the same era, from a different fractionation of thymic extract. Both traditions descend from Abraham White's 1960s thymic-factor work, but the lab lineages and active molecules are not the same. Western clinical adoption of Thymalin has been minimal; the evidence base is concentrated in Russian-language literature and has not been independently replicated in Western laboratories at scale.
How It Works
Thymalin helps restore the immune system by supporting the thymus gland — the organ responsible for training immune cells. As we age, the thymus shrinks, and Thymalin may help compensate for this decline.
Thymalin acts on the neuroendocrine-immune axis by promoting T-cell maturation and differentiation. Its constituent dipeptides (EW and KE) modulate cytokine production, enhance natural killer cell activity, and regulate proliferative activity in monocyte/macrophage lineages. It activates differentiation of hematopoietic stem cells and supports the restoration of thymic tissue. Studies demonstrate it influences gene expression related to immune function, cellular aging, and inflammation, potentially through epigenetic mechanisms. Research also shows a functional relationship between thymalin and pineal gland peptides in regulating the neuroendocrine-immune axis during aging.
Evidence Snapshot
Human Clinical Evidence
Moderate. A key randomized trial showed thymalin plus epithalamin reduced mortality nearly 2-fold in elderly patients over 6 years. Additional clinical studies in Russia demonstrate immune restoration in elderly and immunocompromised patients, and early clinical data supports use in COVID-19 complex therapy. Western clinical trials are lacking.
Animal / Preclinical
Extensive. Animal studies show immune restoration, reduced tumor incidence, extended lifespan, and anti-carcinogenic effects of the synthetic thymalin dipeptide L-Glu-L-Trp. Preclinical work demonstrates hematopoietic stem cell differentiation activation and thymus regeneration in aged animals.
Mechanistic Rationale
Moderate-to-strong. The active dipeptides EW and KE have been identified and shown to regulate gene expression involved in immune and inflammatory pathways. Thymic function restoration is well-understood, and the neuroendocrine-immune axis connection with pineal peptides adds mechanistic depth.
Research Gaps & Open Questions
What the current literature has not yet settled about Thymalin:
- 01Independent replication outside the Khavinson research program and Russian clinical network — the substantial Russian clinical history has not been reproduced under Western trial-methodology standards.
- 02Modern blinded randomized controlled trials with rigorous endpoint adjudication for any indication, including the flagship elderly-cohort longevity claim.
- 03Pharmacokinetics in humans — the heterogeneous nature of the preparation makes ADME characterization complicated, and it has not been done by Western standards.
- 04Component identification at scale — while EW and KE dipeptides are identified as active fractions, the full active-component profile of the Thymalin extract is not exhaustively characterized.
- 05Long-term safety with cumulative repeated courses — the lifelong-repeated-course schedule used in Russian longevity protocols has not been evaluated by independent Western pharmacovigilance.
- 06Theoretical cancer-promotion concern — immune stimulation in patients with subclinical malignancy or strong cancer-family history is a class concern that Russian observational data does not adequately address.
Forms & Administration
Thymalin is typically administered via intramuscular injection. Treatment courses are usually short (5-10 days) and may be repeated periodically. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Russian clinical protocols use 5–30 mg per intramuscular injection per day, typically reconstituted from lyophilized powder. Outside Russian pharmaceutical channels, research-chemical Thymalin is sold for injection at similar dose ranges, with anecdotal protocols often citing 10 mg/day as a starting point.
Frequency
Daily intramuscular injection across a short course. Some Russian protocols split into multiple injections per day for severe immune dysfunction; most use single daily dosing.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
5–10 day courses are the most commonly described schedule, repeated every 3–6 months — a characteristic feature of Khavinson protocols. The flagship elderly-cohort study used repeated short courses over several years.
Protocol Notes
Thymalin is supplied in Russia as a lyophilized powder for reconstitution, typically with sterile saline rather than bacteriostatic water. Outside Russian pharmaceutical channels, research-chemical Thymalin quality is variable and unverified; the heterogeneous nature of the original extract means that 'Thymalin' from different sources may not contain the same component profile even at matched labeled mass. Western clinicians do not generally prescribe Thymalin, and protocols outside Russia rely on convention and forum consensus rather than anchored clinical guidance.
Claims for Thymalin's broader anti-aging and longevity effects exceed what the evidence base, dominated by single-program research, can independently support. Not FDA-approved. The Russian protocol tradition is methodologically variable by modern standards, and research-chemical supply outside Russian pharmaceutical channels is not authorized for human use.
Timeline of Effects
Onset
Not characterized by controlled clinical trials of modern standard. Russian clinical reports describe immune-parameter normalization (T-cell count, lymphocyte function) within the duration of a 5–10 day course. Subjective symptomatic effects in immunocompromised contexts are typically reported within the same window.
Peak Effect
Russian protocols measure outcomes at the end of a 5–10 day course and at follow-up visits over weeks to months. The flagship elderly-cohort study reports mortality outcomes over multi-year follow-up of repeated courses; individual peak effect is not well characterized for casual users.
After Discontinuation
No documented withdrawal syndrome. Immune-parameter changes from a single course are typically transient — fading over weeks to months — which is the rationale for the repeated-course schedule used in Russian protocols. Long-term effects of cumulative repeated courses, beyond the Khavinson cohort observations, have not been independently studied.
Monitoring & Measurement
Bloodwork & Labs
- •CBC with differential — total lymphocytes and CD4 / CD8 subsets; the most widely-available immune-cell readout
- •hs-CRP
- •Quantitative immunoglobulins (IgG, IgA, IgM)
- •NK cell count via flow cytometry — specialty panel, more expensive but directly tests mechanism
Functional & Performance Tests
- •Structured illness frequency and duration diary — the real-world endpoint that matters
- •Subjective recovery-from-illness tracking
When to Test
Baseline, 12 weeks, and 24 weeks. Illness diary continuous.
Interpretation & Notes
Thymalin is a calf-thymus extract rather than a single defined peptide — its heterogeneous composition means you're measuring the effect of a preparation, not a molecule, and batch-to-batch variance in activity is larger than with synthetic Tα1. The measurement setup is otherwise the same as for Tα1: CBC with differential plus a structured infection diary, looking for a 3–6 month trend in infection frequency or severity rather than a single bloodwork inflection. Most clinical evidence for Thymalin is Russian-published and not well-replicated in Western trials, which makes honest measurement especially important — you're essentially running an n-of-1 experiment on a preparation with limited international validation. Standard CBC and immunoglobulin panels via LabCorp or Quest direct-to-consumer; NK-cell flow cytometry typically requires a clinician order.
Common Questions
Who Thymalin Is NOT For
- •Pregnancy — no adequate reproductive toxicology data; not recommended.
- •Breastfeeding — no data on transfer or infant effects.
- •Active autoimmune disease — immunostimulation in an autoimmune context could theoretically worsen disease activity; requires careful clinician evaluation.
- •Active or recent-history hematologic malignancy — immune-cell stimulation in lymphoid malignancy contexts is theoretically concerning and warrants oncology clinician input.
- •Pediatric use — limited safety and developmental data outside Russian clinical practice.
- •Known hypersensitivity to thymic peptide preparations, to bovine/calf-derived products, or to excipients used in reconstitution. Research-chemical supply quality and unknown sterility raise additional injection-site infection risk absent from clinic-supplied medication.
Drug & Supplement Interactions
Documented clinical drug interactions for Thymalin are limited. Russian clinical literature reports concurrent use with antibiotics, chemotherapy, antiviral therapy, and tuberculostatic regimens as adjunctive immunocorrection without flagged interactions, but these reports do not meet modern formal interaction-study standards. Theoretical class concerns include: concurrent use with immunosuppressive agents (corticosteroids at immunosuppressive doses, calcineurin inhibitors, biologics targeting T-cell function) — Thymalin's intended T-cell-supportive activity would be expected to oppose those agents' purpose, and concurrent use is not consistent with the prescribing rationale for those drugs. Co-administration with vaccines is sometimes discussed positively in Russian clinical contexts but has not been validated by Western studies. Patients on any regular medication should disclose Thymalin use to their prescribing clinician.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved in the US
- • Quality varies by source
- • Should be used under clinician guidance
What We Don't Know
Western clinical trial data is limited. Most evidence comes from Russian clinical practice and publications.
Legal Status
United States
Not FDA-approved for any indication. Not recognized as a dietary supplement ingredient. Not on the FDA's list of peptides eligible for 503A compounding. Sold primarily through research-chemical suppliers not authorized for human use. Unclear whether any US-licensed clinics administer it; legitimate clinical access pathways are essentially absent.
International
Registered as a pharmaceutical in Russia and several CIS states, where it has been in continuous clinical use since the 1970s–80s for immunocorrection in elderly, post-surgical, and infectious-disease contexts. Not approved by EMA, MHRA, Health Canada, or TGA. Outside the CIS, it is generally unavailable through legitimate clinical channels.
Sports & Competition
Not specifically named on the WADA Prohibited List, but as a parenteral preparation without governmental health authority approval in most WADA-code jurisdictions, the WADA S0 catch-all category likely applies for athletes outside Russia. Russian-approved status does not necessarily exempt it under WADA rules.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Thymalin is approved or recognized in the West as an immunomodulator.
Reality
It is not. Thymalin has decades of registered use in Russia and CIS states but no approval from the FDA, EMA, MHRA, Health Canada, or TGA. Russian regulatory approval does not equal Western approval, and Western clinical adoption is essentially absent.
Myth
Thymalin and Thymosin Alpha-1 are the same thing.
Reality
They are distinct preparations from different research lineages. Thymalin is a heterogeneous peptide complex from the Khavinson program; Thymosin Alpha-1 is a single 28-amino-acid peptide identified independently by Allan Goldstein's group. Both descend from Abraham White's 1960s thymic-factor work, but they are not interchangeable and have different evidence bases.
Myth
Russian-approved means Western-equivalent safety and efficacy validation.
Reality
Russian pharmaceutical registration and modern Western drug approval are different processes with different evidence requirements. Russian approval reflects an internal regulatory verdict on data assembled within that system, not independent validation under Western-standard trial methodology. The two should not be treated as equivalent.
Myth
Vladimir Khavinson won the Nobel Prize for peptide bioregulator research.
Reality
He did not. The Khavinson group has published extensively and Thymalin is one of the better-documented entries in their catalog, but Nobel-level recognition has not occurred and core program claims have not been independently replicated in Western laboratories.
Myth
Because Thymalin is a 'natural' tissue extract, it is automatically safer than synthetic peptides.
Reality
Biological origin does not equal safety. Calf-thymus extraction introduces allergenicity considerations, the heterogeneous composition increases the chance of unidentified immunogenic components, and the parenteral route carries injection-site and infection risks. Russian clinical use under medical supervision is a different risk profile than research-chemical self-administration.
Published Research
17 studiesExpression features of T-lymphocytes, B-lymphocytes and macrophages in the post-traumatic regenerate of the mandible rats under conditions of thymalin injection.
The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19.
Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line.
Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19.
Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells.
Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo.
[Characteristics of the pineal gland and thymus relationship in aging].
[Immunological correction in progressive pulmonary tuberculosis].
Peptides of pineal gland and thymus prolong human life.
Contemporary Views on the Nature and Clinical Application of Thymus Preparations.
[Geroprotective effect of thymalin and epithalamin].
Age-related changes of thymalin content in human epidermis.
Peptides and Ageing.
Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats.
Natural and synthetic thymic peptides as therapeutics for immune dysfunction.
[The protective effect of peptides from the thymus and tracheal mucosa in an experimental respiratory influenzal infection].
[Correction with thymic and bone marrow peptides of radiation injuries of immuno- and hemopoiesis].
Quick Facts
- Class
- Thymic Peptide
- Tier
- C
- Evidence
- Moderate
- Safety
- Moderate Data
- Updated
- Mar 2026
- Citations
- 17PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.